Tumor Atlas
Cancer is a complex disease of genomic alterations, exploiting many different molecular mechanisms. Fighting cancer requires comprehensive knowledge of functionally disrupted genes and cell types (including stromal and immune cells) across all cancer types. To tackle this challenge, we are utilizing a range of technologies to characterize the genomes, exomes, transcriptomes, proteomes, methylomes and cellular landscape across more than 50 tumor types and subtypes.
Ó³»´«Ã½ Cancer Program scientists have played key roles in and the projects. Over 18,000 tumors have been genomically characterized and analyzed at the Ó³»´«Ã½ to date, including those from patients of particular clinical interest. Clinical cancer sequencing continues to expand at the . Excitingly, scientists in the Cancer Program and Klarman Cell Observatory have collaborated to generate the first glimpses of tumors at the single cell level (including immune infiltrates), providing unprecedented resolution into the genomes of tumors. And, Ó³»´«Ã½ scientists have developed new approaches to make it possible to sample cancer genomes using blood biopsies. New efforts directly engaging cancer patient populations, such as the , will greatly accelerate the pace of this research.
Our long-term goal is to comprehensively characterize the genetic and immunological components of over 100,000 cancer samples with corresponding clinical data, and make such data broadly available as part of the .
Projects
- - Regularly updated analyses and aggregated TCGA data can be found on the portal and site.
- Cancer Genome Analysis
- Genomic Mechanisms of Resistance and Response
- Clinical Cancer Genomics & Precision Medicine
- The Slim Initiative for Genomic Medicine
- Direct-to-patient cancer research projects
- Blood Biopsy Initiative
Results and data from our many projects can be accessed via Ó³»´«Ã½ Data, Software and Tools.
